View abstract

This abstract is assigned to sessions

Title

Is Olisense the new Holy Grail for corneal neovascularization after infectious keratitis?

Purpose	To describe the clinical response of corneal neovascularization following Acanthamoeba keratitis in a patient treated with Olisense (Aganirsen, GS-101), a novel antisense mRNA eye drop with anti-angiogenic properties.
Methods	A patient with PCR-confirmed Acanthamoeba keratitis developed progressive corneal opacification and neovascularization despite intensive antimicrobial therapy. Once the infection was clinically quiescent and no antimicrobial treatment was needed, adjunctive therapy with Olisense was initiated.
Results	After one month of Olisense therapy, slit-lamp evaluation revealed decreased vascular congestion and regression of neovascularization, while the overall corneal opacification remained stable. The treatment was well tolerated and no adverse ocular effects were observed, supporting the safety profile reported in earlier trials.
Conclusion	Olisense is an antisense oligonucleotide that selectively downregulates fibroblast growth factor receptor-1 expression, thereby inhibiting angiogenic signalling and thus corneal neovascularization. Previous studies have shown efficacy in herpetic and inflammatory keratitis with significant reduction of neovascular surface area. This case highlights its potential role in post-infectious keratitis, where regression of pathologic vascularization may improve long-term prognosis and graft survival after keratoplasty. Olisense represents a valuable adjunct to the management post-infectious corneal neovascularization.
Conflict of interest	No

Authors 1

Initials	M
Last name	Lauwers
Department	UZ Leuven
City	Leuven

Authors 2

Initials	H
Last name	Delbeke
Department	UZ Leuven
City	Leuven